Targeted therapy for cancer stem-like cells of non-small cell lung cancers with inhibition of the cJun transcription factor
Project/Area Number |
23591132
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | Hokkaido University |
Principal Investigator |
KINOSHITA Ichiro 北海道大学, 医学(系)研究科(研究院), 准教授 (40343008)
|
Co-Investigator(Kenkyū-buntansha) |
SHIMIZU Yasushi 北海道大学, 大学病院, 助教 (10374513)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 肺癌 / 癌幹細胞 / cJun / EZH2 / 幹細胞 / cJun / HDAC / エピジェネティクス / 分子標的薬 |
Research Abstract |
Sphere forming capacity under serum-free culture, indicative of cancer stem cells, were decreased by cJun inhibition in non-small lung cancer (NSCLC) cells, while sphere forming cells did not show enhanced tumorigenicity in SCID mice. Meanwhile, an inhibitor of histone methyltransferase EZH2 involved in stem cell maintenance via epigenetic regulation suppressed growth of NSCLC cells. An inhibitor of histone deacetylase (HDAC), another epigenetic regulator, showed a synergistic growth suppressive effect with the EZH2 inhibitor. Combined epigenetic therapy with an EZH2 inhibitor and an HDAC inhibitor may represent an effective approach for NSCLCs.
|
Report
(4 results)
Research Products
(23 results)
-
-
-
[Journal Article] TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance.2013
Author(s)
Baghdadi M, Yoneda A, Yamashina T, Nagao H, Komohara Y, Nagai S, Akiba H, Foretz M, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Takeya M, Viollet B, Yagita H, Jinushi M
-
Journal Title
Immunity
Volume: 39
Issue: 6
Pages: 1070-1081
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells2012
Author(s)
Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H
-
Journal Title
Lung Cancer
Volume: 78
Issue: 2
Pages: 138-143
DOI
Related Report
Peer Reviewed
-
[Journal Article] Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. S.2012
Author(s)
Chiba, M. Baghdadi, H. Akiba, H. Yoshiyama, I. Kinoshita, H. Dosaka-Akita, Y. Fujioka, Y. Ohba, J. V. Gorman, J. D. Colgan, M. Hirashima, T. Uede, A. Takaoka, H. Yagita and M. Jinushi.
-
Journal Title
Nat. Immunol.
Volume: 13
Issue: 9
Pages: 832-842
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer2011
Author(s)
Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Takeda K, Aburatani H, Oizumi S, Konishi J, Kaga K, Matsuno Y, Birrer MJ, Nishimura M and Dosaka-Akita H
-
Journal Title
Lung Cancer
Volume: 72
Issue: 2
Pages: 229-237
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-